213 related articles for article (PubMed ID: 28602747)
1. Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.
Santos-Lobato BL; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
Nitric Oxide; 2018 Apr; 74():86-90. PubMed ID: 28602747
[TBL] [Abstract][Full Text] [Related]
2. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
3. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.
Santos-Lobato BL; Schumacher-Schuh AF; Rieder CRM; Hutz MH; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
Arq Neuropsiquiatr; 2020 Apr; 78(4):206-216. PubMed ID: 32294749
[TBL] [Abstract][Full Text] [Related]
5. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.
Santos-Lobato BL; Bortolanza M; Pinheiro LC; Batalhão ME; Pimentel ÂV; Capellari-Carnio E; Del-Bel EA; Tumas V
J Neural Transm (Vienna); 2022 Jan; 129(1):55-63. PubMed ID: 34940921
[TBL] [Abstract][Full Text] [Related]
7. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
Ivanova SA; Alifirova VM; Pozhidaev IV; Freidin MB; Zhukova IA; Osmanova DZ; Zhukova NG; Mironova YA; Tiguntsev VV; Fedorenko OY; Bokhan NA; Wilffert B; Loonen AJM
J Pharm Pharm Sci; 2018; 21(1):340-346. PubMed ID: 30075828
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
Suh DC; Pahwa R; Mallya U
J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
12. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Stathis P; Konitsiotis S; Tagaris G; Peterson D;
Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
[TBL] [Abstract][Full Text] [Related]
13. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
[TBL] [Abstract][Full Text] [Related]
14. Quantitative motor assessment of dyskinesias in Parkinson's disease.
Schaeffer E; Maetzler W; Liepelt-Scarfone I; Sass C; Reilmann R; Berg D
J Neural Transm (Vienna); 2015 Sep; 122(9):1271-8. PubMed ID: 25712401
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
Redenšek S; Flisar D; Kojović M; Kramberger MG; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
J Neuroinflammation; 2019 Feb; 16(1):50. PubMed ID: 30813952
[TBL] [Abstract][Full Text] [Related]
16. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
17. Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease.
Soares NM; Pereira GM; Dutra ACL; Artigas NR; Krimberg JS; Monticelli BE; Schumacher-Schuh AF; Almeida RMM; Rieder CRM
Arq Neuropsiquiatr; 2023 Jan; 81(1):40-46. PubMed ID: 36918006
[TBL] [Abstract][Full Text] [Related]
18. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
Foltynie T; Cheeran B; Williams-Gray CH; Edwards MJ; Schneider SA; Weinberger D; Rothwell JC; Barker RA; Bhatia KP
J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):141-4. PubMed ID: 18977816
[TBL] [Abstract][Full Text] [Related]
19. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
